Epidemiology and treatment modalities for the management of benign prostatic hyperplasia

Soum D. Lokeshwar, Benjamin T. Harper, Eric Webb, Andre Jordan, Thomas A. Dykes, Durwood E. Neal, Martha K. Terris, Zachary Klaassen

Research output: Contribution to journalReview article

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. This increasing incidence has brought about a multitude of treatment modalities in the last two decades. With so many treatment modalities available, physicians are tasked with selecting the optimal therapy for their patients. Current therapies can first be divided into medical or surgical intervention. Medical therapy for BPH includes 5-alpha-reductase inhibitors and alpha-blockers, or a combination of both. Surgical interventions include a conventional transurethral resection of the prostate (TURP), as well as newer modalities such as bipolar TURP, holmium laser enucleation of the prostate (HoLEP), Greenlight and thulium laser, and prostatic urethral lift (PUL). Emerging therapies in this field must also be further investigated for safety and efficacy. This narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection.

Original languageEnglish (US)
Pages (from-to)529-539
Number of pages11
JournalTranslational Andrology and Urology
Volume8
Issue number5
DOIs
StatePublished - Jan 1 2019

Fingerprint

Prostatic Hyperplasia
Epidemiology
Transurethral Resection of Prostate
Therapeutics
Thulium
5-alpha Reductase Inhibitors
Lower Urinary Tract Symptoms
Metabolic Diseases
Incidence
Solid-State Lasers
Prostate
Lasers
Obesity
Physicians
Safety

Keywords

  • Benign prostatic hyperplasia (BPH)
  • BPH epidemiology
  • Future therapies
  • Urologic surgery

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. / Lokeshwar, Soum D.; Harper, Benjamin T.; Webb, Eric; Jordan, Andre; Dykes, Thomas A.; Neal, Durwood E.; Terris, Martha K.; Klaassen, Zachary.

In: Translational Andrology and Urology, Vol. 8, No. 5, 01.01.2019, p. 529-539.

Research output: Contribution to journalReview article

Lokeshwar, Soum D. ; Harper, Benjamin T. ; Webb, Eric ; Jordan, Andre ; Dykes, Thomas A. ; Neal, Durwood E. ; Terris, Martha K. ; Klaassen, Zachary. / Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. In: Translational Andrology and Urology. 2019 ; Vol. 8, No. 5. pp. 529-539.
@article{6f09425cfe2e41bfa775e203f9ebfebf,
title = "Epidemiology and treatment modalities for the management of benign prostatic hyperplasia",
abstract = "Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. This increasing incidence has brought about a multitude of treatment modalities in the last two decades. With so many treatment modalities available, physicians are tasked with selecting the optimal therapy for their patients. Current therapies can first be divided into medical or surgical intervention. Medical therapy for BPH includes 5-alpha-reductase inhibitors and alpha-blockers, or a combination of both. Surgical interventions include a conventional transurethral resection of the prostate (TURP), as well as newer modalities such as bipolar TURP, holmium laser enucleation of the prostate (HoLEP), Greenlight and thulium laser, and prostatic urethral lift (PUL). Emerging therapies in this field must also be further investigated for safety and efficacy. This narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection.",
keywords = "Benign prostatic hyperplasia (BPH), BPH epidemiology, Future therapies, Urologic surgery",
author = "Lokeshwar, {Soum D.} and Harper, {Benjamin T.} and Eric Webb and Andre Jordan and Dykes, {Thomas A.} and Neal, {Durwood E.} and Terris, {Martha K.} and Zachary Klaassen",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/tau.2019.10.01",
language = "English (US)",
volume = "8",
pages = "529--539",
journal = "Translational Andrology and Urology",
issn = "2223-4683",
publisher = "AME Publishing Company",
number = "5",

}

TY - JOUR

T1 - Epidemiology and treatment modalities for the management of benign prostatic hyperplasia

AU - Lokeshwar, Soum D.

AU - Harper, Benjamin T.

AU - Webb, Eric

AU - Jordan, Andre

AU - Dykes, Thomas A.

AU - Neal, Durwood E.

AU - Terris, Martha K.

AU - Klaassen, Zachary

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. This increasing incidence has brought about a multitude of treatment modalities in the last two decades. With so many treatment modalities available, physicians are tasked with selecting the optimal therapy for their patients. Current therapies can first be divided into medical or surgical intervention. Medical therapy for BPH includes 5-alpha-reductase inhibitors and alpha-blockers, or a combination of both. Surgical interventions include a conventional transurethral resection of the prostate (TURP), as well as newer modalities such as bipolar TURP, holmium laser enucleation of the prostate (HoLEP), Greenlight and thulium laser, and prostatic urethral lift (PUL). Emerging therapies in this field must also be further investigated for safety and efficacy. This narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection.

AB - Benign prostatic hyperplasia (BPH) is one of the most common conditions affecting men. BPH can lead to a number of symptoms for patients commonly referred to as lower urinary tract symptoms (LUTS). Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. This increasing incidence has brought about a multitude of treatment modalities in the last two decades. With so many treatment modalities available, physicians are tasked with selecting the optimal therapy for their patients. Current therapies can first be divided into medical or surgical intervention. Medical therapy for BPH includes 5-alpha-reductase inhibitors and alpha-blockers, or a combination of both. Surgical interventions include a conventional transurethral resection of the prostate (TURP), as well as newer modalities such as bipolar TURP, holmium laser enucleation of the prostate (HoLEP), Greenlight and thulium laser, and prostatic urethral lift (PUL). Emerging therapies in this field must also be further investigated for safety and efficacy. This narrative review attempts to consolidate current and emerging treatment options for BPH and highlights the need for additional investigation on optimizing treatment selection.

KW - Benign prostatic hyperplasia (BPH)

KW - BPH epidemiology

KW - Future therapies

KW - Urologic surgery

UR - http://www.scopus.com/inward/record.url?scp=85076477935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076477935&partnerID=8YFLogxK

U2 - 10.21037/tau.2019.10.01

DO - 10.21037/tau.2019.10.01

M3 - Review article

AN - SCOPUS:85076477935

VL - 8

SP - 529

EP - 539

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

SN - 2223-4683

IS - 5

ER -